QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations

In This Article:

By M. Marin

NASDAQ:QNRX

READ THE FULL QNRX RESEARCH REPORT

U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations

Quoin Pharmaceuticals (NASDAQ:QNRX) provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance, Quoin initiated testing of the safety and efficacy of QRX003 in a pediatric patient with Netherton Syndrome (NS). NS is a rare inherited genetic disease for which there is currently no approved treatment or cure. This initiative addresses multiple QNRX’s objectives, including studying QRX003 in pediatric patient populations. Treating pediatric patients is important, as early treatment is critical to managing the disease. The company also commenced measures to expand clinical activities on QRX003 internationally. Separately, management raised its stake in QNRX shares, which we view as a positive indicator of its optimism about the company’s prospects.

Key takeaways

  • QNRX initiated assessment of QRX003 in an NS pediatric patient, consistent with 1) plans to extend patient populations eligible to participate in clinical studies and 2) contributing to the growing database to support potential regulatory approval and subsequent commercialization of QRX003

  • Quoin expects to add three additional pediatric patients in Spain shortly

  • With two active late stage clinical trials in the U.S. for NS being conducted concurrently under an open FDA IND application, QNRX is expanding the study to international sites

    • Quoin has identified a center in Saudi Arabia as the 1st international location (and 6th overall site) participating in the study

    • Quoin plans to open two additional clinical sites in the U.K.

  • The CEO and COO increased their investment in QNRX ADSs, which we view positively

  • QNRX is expanding QRX003 optionality, studying it in a pediatric patient with PSS

  • Assessing assets for multiple indications is a core objective that can spread costs over a wider base

Initiating QRX003 assessment in pediatric patient consistent with plans to expand populations eligible to participate in clinical study & expand database for potential regulatory approval…

The company expects the results of the clinical assessment of QRX003 in a young child with NS to contribute to its database to support potential regulatory approval and subsequent commercialization of QRX003. QNRX is also optimistic that the data from this assessment will facilitate its ability to lower the eligibility age for its clinical activities around NS. QRX003 is currently being evaluated for the treatment of NS in two active late-stage studies that are being conducted concurrently in the U.S. in patients 14 years or older under an open IND (Investigational New Drug) application with the FDA.

Waiting for permission
Allow microphone access to enable voice search

Try again.